Elucidating the Neuroprotective Role of PPARs in Parkinson's Disease: A Neoteric and Prospective Target.
Tapan Behl,Piyush Madaan,Aayush Sehgal,Sukhbir Singh,Neelam Sharma,Saurabh Bhatia,Ahmed Al-Harrasi,Sridevi Chigurupati,Ibrahim Alrashdi,Simona Bungau +9 more
Reads0
Chats0
TLDR
In this article, a review of the emerging evidence enlightening the neuroprotective outcomes of PPAR agonists in in vivo and in vitro models experiencing Parkinson's disease is presented.Abstract:
One of the utmost frequently emerging neurodegenerative diseases, Parkinson’s disease (PD) must be comprehended through the forfeit of dopamine (DA)-generating nerve cells in the substantia nigra pars compacta (SN-PC). The etiology and pathogenesis underlying the emergence of PD is still obscure. However, expanding corroboration encourages the involvement of genetic and environmental factors in the etiology of PD. The destruction of numerous cellular components, namely oxidative stress, ubiquitin-proteasome system (UPS) dysfunction, autophagy-lysosome system dysfunction, neuroinflammation and programmed cell death, and mitochondrial dysfunction partake in the pathogenesis of PD. Present-day pharmacotherapy can alleviate the manifestations, but no therapy has been demonstrated to cease disease progression. Peroxisome proliferator-activated receptors (PPARs) are ligand-directed transcription factors pertaining to the class of nuclear hormone receptors (NHR), and are implicated in the modulation of mitochondrial operation, inflammation, wound healing, redox equilibrium, and metabolism of blood sugar and lipids. Numerous PPAR agonists have been recognized to safeguard nerve cells from oxidative destruction, inflammation, and programmed cell death in PD and other neurodegenerative diseases. Additionally, various investigations suggest that regular administration of PPAR-activating non-steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, indomethacin), and leukotriene receptor antagonists (montelukast) were related to the de-escalated evolution of neurodegenerative diseases. The present review elucidates the emerging evidence enlightening the neuroprotective outcomes of PPAR agonists in in vivo and in vitro models experiencing PD. Existing articles up to the present were procured through PubMed, MEDLINE, etc., utilizing specific keywords spotlighted in this review. Furthermore, the authors aim to provide insight into the neuroprotective actions of PPAR agonists by outlining the pharmacological mechanism. As a conclusion, PPAR agonists exhibit neuroprotection through modulating the expression of a group of genes implicated in cellular survival pathways, and may be a propitious target in the therapy of incapacitating neurodegenerative diseases like PD.read more
Citations
More filters
Journal ArticleDOI
Mechanistic Insights Expatiating the Redox-Active-Metal-Mediated Neuronal Degeneration in Parkinson’s Disease
Tapan Behl,Piyush Madaan,Aayush Sehgal,Sukhbir Singh,Md. Khalid Anwer,Hafiz A. Makeen,Mohammed Al-Bratty,Syam Mohan,Simona Bungau +8 more
TL;DR: Conclusively, metal chelators hold the aptitude to elicit the scavenging of mobile/fluctuating metal ions, which in turn culminates in the suppression of ROS generation, and thereby prelude the evolution of PD.
Journal ArticleDOI
Demystifying the Neuroprotective Role of Neuropeptides in Parkinson’s Disease: A Newfangled and Eloquent Therapeutic Perspective
Tapan Behl,Piyush Madaan,Aayush Sehgal,Sukhbir Singh,Hafiz A. Makeen,Mohammed Al-Bratty,Hassan A. Alhazmi,Abdulkarim M. Meraya,Simona Bungau +8 more
TL;DR: NPs exert substantial neuroprotection through regulating paramount pathways indulged in PD advancement, and consequently, might be a newfangled and eloquent perspective in PD therapy.
Journal ArticleDOI
PPARs and Their Neuroprotective Effects in Parkinson’s Disease: A Novel Therapeutic Approach in α-Synucleinopathy?
Isaac Pérez-Segura,Alberto Santiago-Balmaseda,Luis Daniel Rodríguez-Hernández,Adriana Morales-Martínez,Hilda Angélica Martínez-Becerril,P. Martínez-Gómez,Karen M Delgado-Minjares,Citlaltepetl Salinas-Lara,Irma Alicia Martínez-Dávila,Magdalena Guerra-Crespo,Francisca Pérez-Severiano,Luis O Soto-Rojas +11 more
TL;DR: In this article , the reported therapeutic effects of peroxisome proliferator-activated receptor (PPAR) agonists were analyzed in preclinical Parkinson's disease (PD) animal models and clinical trials for PD.
Journal ArticleDOI
The endocannabinoidome mediator N-oleoylglycine is a novel protective agent against 1-methyl-4-phenyl-pyridinium-induced neurotoxicity
Anna Lauritano,Irene Cipollone,Roberta Verde,Hilal Kalkan,Claudia Moriello,Fabio Arturo Iannotti,Vincenzo Di Marzo,Fabiana Piscitelli +7 more
TL;DR: It is observed that OlGly (1 nM), both as treatment and pre-treatment, is able to protect against neuronal damage induced by 24 h MPP+ exposure through PPARα, and using a targeted lipidomics approach, it is demonstrated thatOlGly exerts its effects also through the modulation of the eCBome.
Journal ArticleDOI
Therapeutic Molecular Insights into the Active Engagement of Cannabinoids in the Therapy of Parkinson’s Disease: A Novel and Futuristic Approach
Vaibhav Jain,Tapan Behl,Aayush Sehgal,Sukhbir Singh,Neelam Sharma,Hafiz A. Makeen,Mohammed Al-Bratty,Abdulkarim M. Meraya,Asim Najmi +8 more
References
More filters
Journal ArticleDOI
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases
Michael T. Lin,M. Flint Beal +1 more
TL;DR: Treatments targeting basic mitochondrial processes, such as energy metabolism or free-radical generation, or specific interactions of disease-related proteins with mitochondria hold great promise in ageing-related neurodegenerative diseases.
Journal ArticleDOI
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Tohru Kitada,Shuichi Asakawa,Nobutaka Hattori,Hiroto Matsumine,Yasuhiro Yamamura,Shinsei Minoshima,Masayuki Yokochi,Yoshikuni Mizuno,Nobuyoshi Shimizu +8 more
TL;DR: Mutations in the newly identified gene appear to be responsible for the pathogenesis of Autosomal recessive juvenile parkinsonism, and the protein product is named ‘Parkin’.
Journal ArticleDOI
Peroxisome proliferator-activated receptors: nuclear control of metabolism.
Béatrice Desvergne,Walter Wahli +1 more
TL;DR: This work has shown that direct expression of PPAR mRNAs in the absence of a specific carrier gene results in down-regulation in the activity of other PPARs, and these properties are consistent with those of a “spatially aggregating substance”.
Journal ArticleDOI
Mitochondrial complex I deficiency in Parkinson's disease.
TL;DR: Results indicated a specific defect of Complex I activity in the substantia nigra of patients with Parkinson's disease, which adds further support to the proposition that Parkinson’s disease may be due to an environmental toxin with action(s) similar to those of MPTP.
Journal ArticleDOI
Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators
Julie St-Pierre,Stavit Drori,Marc Uldry,Jessica M. Silvaggi,James Rhee,Sibylle Jäger,Christoph Handschin,Kangni Zheng,Jiandie D. Lin,Wenli Yang,David Simon,Robert M. Bachoo,Robert M. Bachoo,Bruce M. Spiegelman +13 more
TL;DR: Increase in PGC-1alpha levels dramatically protects neural cells in culture from oxidative-stressor-mediated death, providing a potential target for the therapeutic manipulation of these important endogenous toxins.